Defined Terms Section. Action 2.2(e) Affiliate 6.10(a) Agreement Preamble Applicable Procedures 6.10(b) Bank 2.2(b) Burdensome Condition 2.2(d) Closing 1.2(a) Closing Date 1.2(a) Company Preamble Company SEC Reports 2.2(g) Company Subsidiary(ies) 2.2(b) Company’s Knowledge 6.10(f) Contemplated Transactions 2.2(c)(1) DTC 4.2(b) Exchange Act 2.2(d) FDIC 2.2(b) Federal Reserve 2.2(d)
Defined Terms Section. Certificate Section 2.5.2 CGCL Recitals Closing Section 1.2 Closing Date Section 1.2 Code Recitals Combination Cash Election Section 2.2.1 Combination Stock Election Section 2.2.1 Community Reinvestment Act Section 3.7(c) Confidentiality Agreement Section 6.2 Control Transaction Section 11.2 CVBF Preamble CVBF Affiliated Shareholders Recitals CVBF Articles Section 4.2 CVBF Balance Sheet Section 4.9(c) CVBF Bank Recitals CVBF Benefit Plan Section 7.4(a) CVBF Board Section 4.5(a) CVBF Board Approval Section 4.5(b) CVBF Board Recommendation Section 5.3(b) CVBF Bylaws Section 4.2 CVBF Common Stock Certificates Section 2.4(a) CVBF Confidential Disclosure Schedule Article IV Preamble CVBF Fairness Opinion Section 4.26 CVBF Material Contract Section 4.15 CVBF Options Section 7.1(b) CVBF Permits Section 4.8(a) CVBF Property Section 4.20 CVBF SEC Filings Section 4.9(a) CVBF Shares Section 2.1(a) CVBF Termination Fee Section 11.2(c) Effective Time Section 1.2 Election Section 2.2.1 Election Deadline Section 2.2.2 Election Form Section 2.2.1 Election Form Record Date Section 2.2.1 Exchange Agent Section 2.4(a) Exchange Fund Section 2.5.1 FCBS Preamble FCBS Affiliated Shareholders Recitals FCBS Affiliates Section 6.6 FCBS Articles Section 3.2 FCBS Balance Sheet Section 3.8(c) FCBS Bank Recitals FCBS Board Approval Section 3.5(b) FCBS Board Recommendation Section 5.3(b) FCBS Bylaws Section 3.2 FCBS Confidential Disclosure Schedule Article III Preamble FCBS Employees Section 7.4(a) FCBS Fairness Opinion Section 3.26 - 58 - DEFINED TERMS SECTION FCBS Financial Advisor Section 3.26 FCBS Filings List Section 3.8(a) FCBS Filings Section 3.8(a) FCBS Material Contract Section 3.14 FCBS Option Shares Section 3.3(a) FCBS Options Section 2.5 FCBS Permits Section 3.7 FCBS Property Section 3.20 FCBS Shareholders’ Meeting Section 5.2 FCBS Stock Certificates Section 2.4(b) FCBS Termination Fee Section 11.2(b) Governing Law Section 12.13 Hearing Section 5.2(a) Hearing Notice Section 5.2(a) Holding Company Merger Recitals Indemnified Liabilities Section 7.5(a) Indemnified Persons Section 7.5(a) Indemnifying Party Section 7.5(a) Liens Section 3.4 Mailing Date Section 2.2.1 Multiemployer Plan Section 3.11(b) Option Payment Section 2.6 Option Payments Section 2.6 Permit Application Section 5.2(a) Prohibited Transaction Section 3.11(b) Registration Statement on Form S-4 Section 5.2(b) Regulatory Authority Section 3.8(d) Representatives Section 6.2 Stock Election Section 2.2.1 Stock Prorat...
Defined Terms Section. Alliance Manager 3.1 Auditor 10.4(c) Bankruptcy Event 13.5 Bankrupt Party 15.13 Claims 11.1 Clinical Supply Agreement 7.1 Commercialization Plan 6.2(a) Commercial Supply Agreement 7.2(a) Competing Program 15.5(b) Confidentiality Agreement 1.20 DMF 5.1(b) Effective Date Preamble Enforcing Party 9.4(c) Executive Officer 14.1 First Supplemental Development Plan 4.2 GAAP 1.1 Global Development Plan 4.3(d) Global Strategy 4.3(d) Global Territory Expansion Opportunity 6.6 GQP Agreement 5.1(b) ICC 14.2 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Infringement Action 9.5 Initial Development Plan 4.2 Initial Purchase Price Payment 8.5(a)(i) JGAAP 1.1 Joint Inventions 9.1(c)(iii) Joint Steering Committee 3.2(a) Kaken Preamble Kaken Housemarks 9.6(b) Kaken Indemnitees 11.1 Kaken Inventions 9.1(c)(ii) Kaken Product Mark 9.6(a) Kaken Sublicense Agreement 2.1(c) Lilly 1.86 Losses 11.1 Defined Terms Section Major Spruce Partner 2.2 Manufacturing Technology Transfer Agreement 7.2(b) NDA 1.56 Non-Bankrupt Party 15.13 Party Preamble Payment 8.9(b) Pharmacovigilance Agreement 5.8 Product Materials 4.6 Reconciliation Amount 8.5(a)(i) Remedial Action 5.9 Right of Reference 5.5 ROFN 6.6 ROFN Exercise Period 6.6 ROFN Exercise Notice 6.6 ROFN Negotiation Period 6.6 ROFN Offer Notice 6.6 Royalty Term 8.4(b) SEC 12.3(c) Spruce Preamble Spruce Indemnitees 11.2 Spruce Inventions 9.1(c)(i) Spruce Partner 2.2 Step-In Rights 9.2(e) Tax Changing Decision 8.9(b) Tax Documents 8.1 Term 13.1 Territory Development Plan 4.2 Territory Expansion Opportunity 6.6 Transfer Price 8.4(a)(i) Working Group 3.5
Defined Terms Section. Director Section 4.01 Eligibility Criteria Section 3.01(b) Executive Officer Section 5.01(b) FDX API FS-XXXX XXXX Director Director Preamble Preamble Section 4.02(a) Section 4.02 Ineligible Member Section 3.05 Liquidators Section 9.01 Losses Section 7.01(a) Membership Dues Section 3.03 Membership Termination Event Section 3.05 Officers Section 5.01(b) Other Activity Section 6.02(b) President Section 5.01(a) Secretary Section 4.15 Surviving Entity Definition – Change of Control Transfer Working Groups ARTICLE 2 Section 2.11 Section 4.17
Defined Terms Section. Signing Backlog 2.5(b) Software License Agreement 1.8(b)(ix) Specified IP 9.11 Subcontract Agreement 1.8(b)(vi) Sublease 1.8(b)(viii) Tax Contest 8.4(b)(i) Tax Returns Article X Taxes Article X Taxing Authority 8.4(a) Third Party Article X Trade Compliance Laws Article X Transaction Agreements Article X Transfer Taxes 8.1(c) Transition Services Agreement 1.8(b)(x) U.S. Acquired Assets 1.1 U.S. Assumption Agreement 1.4(a) U.S. Buyer Preamble
Defined Terms Section. 3D Medicines Preamble 3D Medicines Housemarks 9.6(b) 3D Medicines Indemnitees 11.1 3D Medicines Inventions 9.1(c)(ii) 3D Medicines Product Xxxx 9.6(a) 3D Medicines Sublicense Agreement 2.1(c) Accused Party 9.5 Agreement Preamble Alliance Manager 3.1 Aravive Preamble Aravive Indemnitees 11.2 Aravive Inventions 9.1(c)(i) Aravive Licensed Product Opportunity 6.6 Aravive Partner 2.2 Auditor 10.4(c) BLA 1.55 Claims 11.1 Clinical Supply Agreement 7.1(a) Commercialization Plan 6.2(a) Competing Program 15.6(b) Confidentiality Agreement 1.24 Development Plan 4.2 Development Proposal 2.1(a) Effective Date Preamble Enforcing Party 9.4(c) Executive Officer 14.1 First Supplemental Development Plan 4.2 GAAP 1.1 ICC 14.2 IFRS 1.1 Indemnified Party 11.3 Indemnifying Party 11.3 Infringement 9.4(a) Infringement Action 9.5 Initial Development Plan 4.2 Joint Inventions 9.1(c)(iii) Joint Steering Committee 3.2(a) Losses 11.1
Defined Terms Section. Manufacturing Technology Transfer Agreement 7.1(b) NDA 1.55 New Studies 2.1(a) Party Preamble Pharmacovigilance Agreement 5.8 Product Materials 4.6 Remedial Action 5.9 ROFN 6.6 ROFN Exercise Period 6.6 ROFN Exercise Notice 6.6 ROFN Negotiation Period 6.6 ROFN Offer Notice 6.6 XXX 2.5(b) XXX Exercise Period 2.5(b) XXX Exercise Notice 2.5(b) XXX Negotiation Period 2.5(b) XXX Offer Notice 2.5(b) Royalty Term 8.6(b) SEC 12.3(c) Stanford 1.76 Step-In Rights 9.2(d) Term 13.1 VAT 8.11(c) Working Group 3.5
Defined Terms Section. Accredited Investor...................................................................2.27(a)(iii) Acquisition Transaction...............................................................6.2(d) Agreement.............................................................................Preamble Blue Sky laws.........................................................................2.27(d) Closing...............................................................................1.3
Defined Terms Section. 2014 Notes 6.20 2019 Notes 6.20 2034 Notes 6.20 Acquisition Proposal 6.2(b)(i) Actions 5.1(g)(i) Affected Employees 6.9(a) Affiliate 5.1(a)(i) Agreement Preamble Alternative Acquisition Agreement 6.2(c)(i)(B) Antitrust Law 6.5(e)(vi) Apparel Business 5.1(a)(iv) Applicable Date 5.1(e)(i) Articles of Merger 1.3 Assumption Period 6.14(e)(vii) Bankruptcy and Equity Exception 5.1(c)(i) beneficial ownership 5.2(i) Breach End Date 8.3(b) Business Day 1.2 Bylaws 2.2 Carveout Transactions Recitals Certificate 4.1(a) Change of Recommendation 6.2(c)(ii) Charter 2.1 Chosen Courts 9.5(a) Closing 1.2 Closing Date 1.2 Code 4.2(g) Collective Bargaining Agreements 5.1(m)(i)
Defined Terms Section. Company Preamble Company Disclosure Letter 5.1 Company Expenses 8.5(c) Company Expenses Cap 8.5(c) Company Financial Statements 5.1(e)(v) Company Material Adverse Effect 5.1(a)(ii) Company Material Contract 5.1(q)(i)(M) Company Plans 5.1(h)(i) Company Recommendation 5.1(c)(ii) Company Required Governmental Approvals 5.1(d)(i) Company Requisite Vote 5.1(c)(i) Company SEC Reports 5.1(e)(i) Compliant 6.14(f)(vi) Confidentiality Agreement 9.7
